12:00 AM
 | 
May 11, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Fluidosomes Tobramycin regulatory update

FDA granted Orphan Drug designation for Axentis' Fluidosomes Tobramycin to treat pulmonary infections caused by Pseudomonas aeruginosa in patients...

Read the full 75 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >